CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)drug
Likely dose
Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02064985
NCT02064985Phase 4Completed
CompareCT.gov

An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease

AstraZeneca·interventional·Posted Feb 17, 2014·Updated May 11, 2016

In Brief

A Phase 4 clinical trial evaluating Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor) for Stable Coronary Heart Disease (CHD). Completed, enrolled 61 participants across 1 site.

Detailed Summary

open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Coronary Heart Disease (CHD)
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 17, 2014
Enrollment StartFeb 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.4 years ago

Interventions

Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)drug

To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).